Director, Health Law Institute, Schulich School of Law, Associate Professor, Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS.
James McGill Professor, Faculty of Law and Faculty of Medicine, McGill University, Montreal, QC.
Healthc Policy. 2022 May;17(4):15-25. doi: 10.12927/hcpol.2022.26830.
Publicly funded research has contributed enormously to many products that were developed in the face of the COVID-19 pandemic. Yet universities' technology transfer practices have failed to ensure that these products are available in low- and middle-income settings. Drawing upon the example of the lipid nanoparticle delivery technology - which was developed in and around the University of British Columbia in Vancouver, BC, and incorporated into the Pfizer/BioNTech COVID-19 vaccine - we show the divide between the university's stated principles to serve global health and technology transfer in practice. We outline three policy actions to realign universities' technology transfer practices in the service of global health.
公共资助的研究为许多应对 COVID-19 大流行而开发的产品做出了巨大贡献。然而，大学的技术转让实践未能确保这些产品在低收入和中等收入环境中可用。我们以脂质纳米颗粒输送技术为例，该技术是在不列颠哥伦比亚省温哥华的英属哥伦比亚大学及其周边地区开发的，并被纳入辉瑞/生物技术公司的 COVID-19 疫苗中，展示了大学在服务全球健康和技术转让实践方面的原则之间的鸿沟。我们概述了三项政策行动，以调整大学的技术转让实践，为全球健康服务。
Zotero 插件